Skip to main content
Medical information Clinical review pending

Genetic Testing

JAK2 Gene Leukemia Acute Myelogenous Genetic Test

This genetic test identifies mutations in the JAK2 gene, which can be associated with acute myelogenous leukemia (AML). It uses Next Generation Sequencing (NGS) technology to help guide treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube). Confirm with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is required for this test. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the JAK2 Gene Leukemia Acute Myelogenous Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of acute myelogenous leukemia (AML).
  • ✓Prognosis assessment in AML.
  • ✓Guiding treatment decisions for AML.
  • ✓Investigating symptoms like fatigue, fever, bruising, or infections.
  • ✓Patients with a family history of leukemia or related blood disorders.
02

In plain language

What this test helps you understand

This test helps identify JAK2 gene mutations associated with acute myelogenous leukemia (AML), aiding in diagnosis, prognosis, and treatment planning.
The JAK2 Gene Leukemia Acute Myelogenous NGS Genetic DNA Test is a diagnostic tool used in the management of acute myelogenous leukemia (AML). It utilizes Next Generation Sequencing (NGS) technology to identify specific mutations within the JAK2 gene. These mutations are sometimes linked to the development of AML and other cancers. Understanding the presence of these mutations can provide valuable information for healthcare providers in developing personalized treatment plans. This test measures the presence of mutations in the JAK2 gene, which can contribute to abnormal cell growth in certain blood cancers. It is designed to help doctors understand the genetic factors influencing a patient's condition. Individuals experiencing symptoms like persistent fatigue, fever, unexplained bruising or bleeding, frequent infections, or unintentional weight loss may be advised to consider this test. Patients with a family history of leukemia or related blood disorders should also discuss this test with their doctor. Taking this test can aid in the early detection of relevant genetic mutations, support informed treatment decisions, and contribute to a personalized approach to cancer care. Discussing the results with your oncologist is essential to understand their meaning and implications for your health management. We offer convenient access to this test through our branches in Nairobi, Mombasa, and Kisumu, as well as home sample collection services.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this test. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube). Confirm with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) of the JAK2 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific mutations in the JAK2 gene. It may not detect all possible genetic changes associated with AML. Results should be interpreted in conjunction with other clinical and laboratory findings. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The JAK2 gene provides instructions for making a protein involved in cell growth and blood cell production. Mutations in this gene can sometimes lead to uncontrolled cell growth.
Acute Myelogenous Leukemia (AML) is a type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells.
Identifying JAK2 mutations can help doctors understand the specific type of AML a patient has, predict how it might respond to treatment, and choose the most effective therapy.
Your doctor will interpret the results in the context of your overall health and other test findings. A positive result indicates the presence of a JAK2 mutation.
A blood sample is typically required for this test. We offer sample collection at our branches or through home visits.
Turnaround time varies. Please contact the laboratory for specific details regarding this test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp